Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
11 mai 2023 16h02 HE
|
Nkarta, Inc.
Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023Cash and cash equivalents of $332.1 million on March 31, 2023Cash runway...
Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
11 mai 2023 16h01 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that...
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
17 avr. 2023 17h01 HE
|
Nkarta, Inc.
Improved ADCC with ADAM17 gene knockout of NK or CAR NK cells, supporting ADAM17 KO use for clinical applications Increased specific killing of cancer cells in vitro by the combination of NKX101 and...
Nkarta to Participate at Upcoming Investor Conferences
12 avr. 2023 21h06 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Announces Departure of Chief Financial & Business Officer
30 mars 2023 16h01 HE
|
Nkarta, Inc.
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage...
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
16 mars 2023 16h01 HE
|
Nkarta, Inc.
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 20232022 year-end cash and cash equivalents of $354.9 millionCash runway anticipated to fund operations into 2025 ...
Nkarta to Participate at Upcoming Investor Conferences
09 févr. 2023 08h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
09 janv. 2023 16h30 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
05 déc. 2022 07h02 HE
|
Nkarta, Inc.
7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle...
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
02 déc. 2022 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...